But whether that's good or bad isn't yet clear
This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
It produced lower 5-year recurrence rates compared to tamoxifen, but didn't boost overall survival, study finds
We care about your feedback. Let us know how we can improve your CancerCompass experience.